The Filing Desk

Cardiff Oncology

CRDF · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

CRDF · Last close · November 19, 2026
$0.89
Value Cardiff Oncology yourself

Cardiff Oncology's revenue fell 13.2% to $1 million in fiscal 2025. Its operating margin was −8,256.3%, down from −7,123.1% a year earlier. Free cash flow was −$38 million. The diluted share count rose 40.3%.

CARDIFF ONCOLOGY, INC. Latest fiscal year ended December 31, 2025 10-K filed February 24, 2026 · 0001193125-26-067464 Updated
Revenue
$1M
13.2%
Operating margin
−8,256.3%
1133.2 pts
Net income
−$46M
 
Free cash flow
−$38M
 
Return on equity
−71.5%
11.9 pts
Market cap
$68M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Cardiff Oncology does

Cardiff Oncology is a clinical-stage biotech company, which means it is still testing its medicine in people and has none approved for sale. Its only drug candidate is onvansertib, a pill that blocks PLK1, a protein cancer cells need to divide. The company tests it alongside standard cancer treatments.

Its main study is a mid-stage (Phase 2) trial in people newly treated for colorectal cancer that has spread and carries a RAS gene mutation. The trial enrolled 110 patients and is run with Pfizer Ignite, a Pfizer service for biotech companies. If the results support it, Cardiff plans a late-stage (Phase 3) trial aimed at approval by the FDA. Doctors are also running their own trials of the drug in pancreatic, small cell lung and triple negative breast cancer, and in a blood cancer called CMML.

Cardiff does not sell any products. It licenses the patents behind onvansertib from Nerviano Medical Sciences, which in February 2026 said Cardiff was in material breach of their license. The company had 31 employees in February 2026, and has said there is substantial doubt it can keep operating without raising more money.

Its biggest risks, as it describes them

  • It will need to raise a lot more money and may not be able to keep going, as it has warned.
  • Onvansertib, its only drug candidate, may fail in trials, cause harmful side effects or never win approval.
  • Nerviano could end the license behind onvansertib over the breach it alleges.
  • Its reliance on outside companies to make the drug and run its trials.
  • It has never earned a profit and may never do so.
From Cardiff Oncology's annual report on Form 10-K, filed February 24, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Cardiff Oncology lost money in fiscal 2025: a net loss of $46 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments141105759258
Debt incl. finance leases00000
Net debt (negative means net cash)−141−105−75−92−58
Net debt to EBITDA—————
Debt to equity0.0x0.0x0.0x0.0x0.0x
Interest coverage—————
Current ratio22.3x14.2x7.4x7.1x3.7x
Quick ratio22.3x14.2x7.4x7.1x3.7x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Cardiff Oncology's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $1.1 million of Cardiff Oncology shares on the open market, and none sold any.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Jul 14, 2026Gary W PaceDirectorBought687,285$1.46$1.0 millionForm 4
Jul 14, 2026Mani MohindruChief Executive Officer, DirectorBought34,364$1.46$50,171Form 4
Jun 18, 2026Gary W PaceDirectorBought30,000$1.22$36,600Form 4
Jun 18, 2026Mani MohindruChief Executive Officer, DirectorBought24,703$1.21$29,891Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score2 of 82 of 82 of 8
Rule of 40−6,422.1%−5,490.5%−6,415.7%
Altman Z''−5.76−4.62−20.45
Accruals ratio−10.7%−8.7%−10.0%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailFailFail
Current ratio roseFailFailFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassPassFail
F-score2 of 82 of 82 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put Cardiff Oncology side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Cardiff OncologyFY25−13.2%−8,256.3%−6,402.5%——2
PMGC HoldingsFY25——−1,080.5%———Compare
Silence TherapeuticsFY25−98.7%−16,292.8%−11,149.5%———Compare
ImageneBioFY25−77.1%−6,056.4%————Compare
BioRestorative TherapiesFY25−10.3%−4,350.1%−3,031.7%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue0000000011
Revenue growth21.8%32.6%−25.1%−35.3%49.6%−1.9%7.5%26.4%40.0%−13.2%
Gross profit−1−1−00——————
Research and development158811111727333735
Operating income−40−26−17−17−19−29−40−45−49−49
Net income−39−25−16−16−19−28−39−41−45−46
Diluted EPS (US$)−1.37−51.76−8.26−2.80−1.08−0.73−0.89−0.93−0.95−0.69
Diluted shares (millions)30026213944454867
Cash flow
Cash from operations−31−23−13−13−16−23−34−31−38−38
Capital expenditure1000001100
Free cash flow−32−23−13−13−17−23−35−31−38−38
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation8421234456
Balance sheet at fiscal year end
Cash and short-term investments3881210131141105759258
Debt incl. finance leases16100000000
Total assets44121413135150116829762
Total liabilities246467910121416
Shareholders' equity206107128140106708345
Margins and ratios
Gross margin−354.1%−258.4%−57.9%100.0%——————
Operating margin−10,534.9%−5,064.4%−4,507.6%−6,817.8%−5,214.9%−8,037.6%−10,337.3%−9,305.7%−7,123.1%−8,256.3%
Net margin−10,287.8%−4,928.1%−4,351.1%−6,709.7%−5,275.2%−7,880.5%−10,026.9%−8,492.0%−6,651.7%−7,732.0%
Free cash flow margin−8,361.5%−4,626.4%−3,490.2%−5,451.1%−4,515.4%−6,474.9%−9,022.3%−6,448.6%−5,530.4%−6,402.5%
Rule of 40 (growth + FCF margin)−8,339.7%−4,593.8%−3,515.3%−5,486.4%−4,465.8%−6,476.8%−9,014.8%−6,422.1%−5,490.5%−6,415.7%
Return on capital——————————
Return on equity−114.5%−189.6%−198.4%−188.7%−28.5%−21.1%−31.4%−47.1%−59.5%−71.5%
Return on assets−68.0%−88.6%−124.4%−120.4%−26.1%−19.9%−29.1%−41.9%−50.8%−57.6%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Cardiff Oncology's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Cardiff Oncology.